Probes & Primers
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the name given to the 2019 emerging coronavirus strain. COVID-19 is the name given to the disease associated with the virus. SARS-CoV-2 is a new strain of coronavirus that has not been previously identified in humans.
There is not enough epidemiological information at this time to determine how easily and sustainably this virus spreads between people, but it is currently estimated that, on average, one infected person will infect between two and three more. The virus seems to be transmitted mainly via respiratory droplets that people sneeze, cough, or exhale. The virus can also survive for several hours on surfaces such as tables and door handles.
The incubation period for COVID-19 is currently estimated at between two and 14 days. At this stage, we know that the virus can be transmitted when people who are infected show flu-like symptoms such as dry coughing, fever and tiredness. There is evidence suggesting that transmission can occur from an infected person with no symptoms; however, uncertainties remain about the effect of transmission by non-symptomatic persons on the epidemic.
The virus can cause mild, flu-like symptoms such as: fever, cough, difficulty breathing, muscle pain, tiredness. More serious cases develop severe pneumonia, acute respiratory distress syndrome, sepsis and septic shock that can lead to death. Generally elderly people and those with underlying health conditions (e.g. hypertension, diabetes, cardiovascular disease, chronic respiratory disease and cancer) are considered to be more at risk of developing severe symptoms.
The R-DiaSARS-CoV-2TM kit is an in vitro diagnostic medical device (IVDMD) designed to qualitatively detect by real-time PCR the Severe Acute Respiratory Syndrome Coronavirus 2 in nasopharyngeal swabs collected from patients showing symptoms related to this pathogen.